Focusing on the top vs. the middle tier?

If so, you’re not having the

greatest impact.

The U.S. healthcare ecosystem is predominantly focused on the top tier (5%) of the health risk pyramid, disproportionately allotting resources (time and money) to the smallest, sickest population. It is not focused on a preemptive, more cost-effective strategy of moving care upstream (bottom and middle tiers), where it has the greatest chance of preempting, slowing or even potentially stopping progression of chronic disease – like chronic kidney disease – to the top tier.

Imagine if you could intervene at a time when patients would benefit most and significant savings could be realized? Now you can.

TOP TIER
Advanced illness
Requiring complex case management, multiple comorbidities, including patients who lean toward end-of-life needs
MIDDLE TIER
GREATEST INTERVENTION OPPORTUNITY

Moderate to rising risk; multiple chronic conditions
Where most of the higher risk patients with chronic diseases reside and where most of the cost exists
BOTTOM TIER
Healthiest
Utilize preventive and wellness services and primary care support for those who are generally healthy; proactively manage identified chronic conditions.
https://www.hfma.org/topics/hfm/2018/october/61959.html

This dynamic is even more problematic in the
Medicare and CKD populations.

Ninety-five percent of Medicare patients with chronic kidney disease fall into stages 1-3b, which also bears the majority of the cost. That’s why the most meaningful change in care would be to conduct risk assessment for disease progression in early stages 1-3b (typically, middle tier).

$87B

Medicare spend 20191

$37B

Medicare spend 20191

Stage 1

Normal function but evidence of kidney damage

Stage 2

Mild loss of kidney function

Stage 3

Moderate to severe loss of kidney function

Stage 4

Severe loss of kidney function

Transition to ESKD

Stage 5

Kidney failure requires treatment to live

ESKD

Current Neglect
95%

Current Focus
5%

That’s where KidneyIntelX can help.
Actionable risk stratification in stages 1-3b.

KidneyIntelXTM, our laboratory-developed test (LDT), is a highly-reliable, bioprognosticTM methodology, that yields a simple-to-understand, custom risk score, predicting which adult patients with type 2 diabetes and with chronic kidney disease stages 1-3b are at low, intermediate or high risk for rapid progressive decline in kidney function.

When your clinicians combine information gathered through KidneyIntelX with newer cardio- and reno-protective therapies, it’s a win-win. They will know which patients are at higher to lower risk for rapid disease progression, and therefore, can appropriately target resources and medications shown to be more effective at slowing or preempting disease progression and advancing kidney health.

Here’s how our 3-part, proprietary methodology – bioprognosis for kidney health – works:

KidneyIntelX has Received Breakthrough Device Designation from the FDA for Chronic Kidney Disease Prognosis

1

Proprietary biomarkers

Biological factors that are clinically proven – in multiple studies – to be most prognostic for kidney disease (TNFR1, TNFR2, KIM-1).

Read Biomarker Clinical Study here

2

Select clinical features

7 select data points from a patient’s health record (eGFR, UACR, serum calcium, HbA1c, systolic BP, platelets, AST) that are indicative of kidney/other key organ health or dysfunction.

3

Validated algorithm

Machine learning combines these diverse and proprietary data inputs to maximize their value through a patient risk score.

4

Yields a clear and actionable test report:

Risk score + guideline-recommended clinical pathway

Low
Intermediate
High
About Test
See Evidence
Budget Impact Analysis